| Gene symbol | tk |
| GTO ID | GTC0047 |
| Trial ID | NCT00589875 |
| Disease | Brain Glioma |
| Altered gene | tk |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | DNA oncolytic virus |
| Treatment | CAN-2409|aglatimagene besadenove |
| Co-treatment | Valacyclovir|Temozolomide|Radiation therapy |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase IIa Study of AdV-tk + Valacyclovir Gene Therapy in Combination With Standard Radiation Therapy for Malignant Gliomas |
| Year | 2007 |
| Country | United States |
| Company sponsor | Candel Therapeutics, Inc. |
| Other ID(s) | BrTK02 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||||||
|
|||||||||||||||